- Supply chain disruptions due to the COVID-19 pandemic and related travel restrictions and lockdowns.
- Fluctuations in foreign exchange rates.
Huakang Biomedical Holdings Company Limited
Greenhouse gas emissions & sustainability report data
In its 2021 reporting, Huakang Biomedical Holdings Company Limited disclosed greenhouse gas emissions of 121.14 tCO2e/year. By scope: Scope 1: 10.2 tCO2e/year; Scope 2: 105.88 tCO2e/year; Scope 3: 6.02 tCO2e/year. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
121.14 tCO2e/year
2021
Water Usage
1.9K m3/year
2021
Waste
3.9 tons/year (hazardous and non-hazardous combined)
2021
Energy Use
206.4K kWh/year
2021
📊 Emissions by Scope (2021)
| Scope | What it covers | Reported value |
|---|---|---|
| Scope 1 | Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions). | 10.2 tCO2e/year |
| Scope 2 | Indirect emissions from purchased electricity, steam, heat and cooling. | 105.88 tCO2e/year |
| Scope 3 | Other indirect emissions across the value chain (purchased goods, business travel, use of sold products, etc.). | 6.02 tCO2e/year |
New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.
✅ Reported Environmental Achievements
- Reduced GHG emissions by 28.4% per FTE and 25.7% per unit of product sold compared to 2020.
- Reduced hazardous waste generation by 33.3% compared to 2020.
- Reduced non-hazardous waste generation by 8.62% compared to 2020.
🎯 Climate & Sustainability Targets
🔜 Short-term
- Completion of Class II medical devices registration of the sperm nuclear DNA integrity reagent and market launch in 2022.
📅 Medium-term
- Reduce emissions by 10% by 2030.
- Reduce waste generation by 20% by 2030.
- Reduce electricity use by 20% by 2030.
- Reduce water use by 20% by 2030.
🌱 ESG Focus Areas
EnvironmentalSocialGovernance